SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

Lifecore Biomedical, Inc. (NASDAQ:LFCR)

US · Delayed Price · Currency is USD
6.52+2.32 (+55.24%)
 
Market Cap244.56M-8.8%
Revenue (ttm)122.64M-4.8%
Net Income-37.28M+3.7%
EPS-1.10+15.7%
Shares Out37.51M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,003,471
Open6.52
Previous Close4.20
Day's Range6.42 - 6.65
52-Week Range3.63 - 8.98
Beta1.08
AnalystsBuy
Price Target6.39(-1.99%)
Earnings DateNov 3, 2026
Insider Score
––Not scored
LFCR Insider Score

No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.

About LFCR

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Address
3515 Lyman Boulevard, Chaska, MN, 55318, US
Market Cap
245 million
Employees
382
Industrial Classification
Drug Manufacturers - Specialty & Generic
1 Day
+55.24%
5 Days
+46.52%
1 Month
+43.61%
6 Months
+78.14%
1 Year
-8.81%

$LFCR stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LFCR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LFCR's directors and management

Net Shares Purchased by Insiders−1−102025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LFCR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LFCR Revenue by Segment

$34.17MTotal
SegmentRevenue% of All
HA manufacturing$18.61M54.48%
CDMO$15.55M45.52%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LFCR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LFCR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LFCR

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$3.67M
VXFVanguard Extended Market ETF$1.94M
VTWOVanguard Russell 2000 ETF$729.42K
VTWVVanguard Russell 2000 Value ETF$110.63K
RSSLGlobal X - Russell 2000 ETF$57.51K
VTHRVanguard Russell 3000 ETF$8.58K

Estimated from each fund’s disclosed top holdings × AUM

LFCR Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for LFCR yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from LFCR’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.